PROGRAM CHAIRS
Sara Hurvitz, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Oncology Practice
Santa Monica, CA
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, TX
FACULTY PRESENTERS
Sara Hurvitz, MD
Professor of Medicine
David Geffen School of Medicine at UCLA
Director, Breast Cancer Clinical Research Program
Co- Director, Santa Monica – UCLA Outpatient Oncology Practice
Santa Monica, CA
Monica Fornier, MD
Associate Professor
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, NY
PROGRAM OVERVIEW
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.
TARGET AUDIENCE
This CME initiative is designed to meet the educational needs of medical oncologists, advanced practice clinicians, oncology nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
LEARNING OBJECTIVES
After the completion of this program, attendees should be able to:
- Identify the patient who will benefit from CDK 4/6 inhibitor therapy with consideration of patient and disease characteristics and appropriately time its use in the course of the disease
- Recognize commonly associated toxicities of CDK4/6 inhibition, and apply strategies for both the monitoring and management of adverse events associated with their use in patients with metastatic breast cancer
- Utilize methodologies to activate all members of the healthcare team, encourage collaboration, and incorporate shared decision-making and survivorship tools to assist in optimizing patient outcomes and management of adverse events
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Credits: 2.0 ANCC Contact Hour.
CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Hurvitz reports editorial support and research grants paid to UCLA: Ambrx, Amgen, Bayer, Daiichi Sankyo, GNE/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, and Dignitana.
Dr. O’Shaughnessy received honoraria for consulting and advisory boards for AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals, and Takeda.
Dr. Fornier has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures
- Participate in the online activity
- Submit the evaluation form to Med Learning Group
You will receive your certificate upon completion.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: August 31, 2020
EXPIRATION DATE: August 31, 2021
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.